Andras Attila Heczey, M.D.
Picture
Andras Attila Heczey, M.D.
Associate Professor
Positions
- Associate Professor
-
Pediatrics-Oncology
7m视频
Houston, TX US
- Member
-
Dan L Duncan Comprehensive Cancer Center
7m视频
Houston, Texas United States
Addresses
- Texas Children's Hospital, Clinical Care Center (Clinic)
-
6701 Fannin St., 14th floor
Houston, TX 77030
United States
Phone: (832) 822-4242
Education
- Fellowship at Baylor College Of Medicine Affiliate Hospitals
- 01/2012 - Houston, TX United States
- Residency at Children's Hospital Of Los Angeles
- 01/2009 - Los Angeles, CA United States
- M.D. from Semmelweis Medical University
- 09/2002 - Budapest, Budapest Hungary
Certifications
- General Pediatrics
- American Board of Pediatrics
- Pediatric Hematology and Oncology
- American Board of Pediatrics
Professional Interests
- Tumor immunotherapy
- Genetic engineering
Professional Statement
Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of 7m视频, Section of Pediatric Hematology and Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT).His research focuses on developing novel treatments for patients with solid tumors by redirecting the immune system to attack cancer cells.
Dr. Heczey has studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells genetically modified to attack neuroblastoma. This approach is tested in the GINAKIT2 Phase 1 clinical trial in children with relapsed or refractory high-risk neuroblastoma.
https://clinicaltrials.gov/ct2/show/NCT03294954
As the Director of the Liver Tumor Center, Dr. Heczey has developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically engineered T lymphocytes. This approach is evaluated in adults and children with liver cancer in two Phase 1 clinical trials (GLYCAR and GAP respectively).
https://clinicaltrials.gov/ct2/show/NCT02905188
https://clinicaltrials.gov/ct2/show/NCT02932956
Active projects in the lab focus on examining the solid tumor microenvironment components' gene expression and cellular neighbourhood characteristics to understand the immuneescape mechanisms and design effective countermeasures. To overcome the metabolic competition between the tumor cells and effector lymphocytes, the lab is examining ways to engineer T cells. The Heczey Lab's ultimate goal is to develop new genetic engineering strategies to reprogram cells inside the human body, in situ.
Websites
Videos
Selected Publications
- Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, Guo L, Heczey A, Asgharzadeh S, Kim E, Dotti G, Metelitsa LS "." J. Clin. Invest.. 2012 Jun 1;122(6):2221-33. Pubmed PMID:
- "." ; Pubmed PMID:
- Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, Gao X, Guo L, Yvon E, Hicks J, Liu H, Dotti G, Metelitsa LS "." Blood.; Pubmed PMID:
- Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK "." Mol Ther. 2017 Jun 8; Pubmed PMID:
- Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S, Metelitsa LS, Heczey A1 "." Hum Gene Ther. 2017 May 28; Pubmed PMID:
- Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu MF, Bulsara S, Mamonkin M, Metelitsa LS, Heczey A. "." Canc Imm Res. 2020 Jan 17; Pubmed PMID:
- Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, Jin J, Courtney AN, Liu B, Di Pierro EJ, Hicks J, Barragan GA, Ngai H, Chen Y, Savoldo B, Dotti G, Metelitsa LS5 "." Clin Canc Res. 2019 Dec 1; Pubmed PMID:
- Heczey A "." 2019 Aug 7; Pubmed PMID:
- Haines K, Sarabia SF, Alvarez KR, Tomlinson G, Vasudevan S, Heczey A, Roy A, Finegold MJ, Parsons DW, Plon SE, L贸pez-Terrada D "." Pediatr Blood Cancer. 2019 Jul; Pubmed PMID:
- Sumazin P, Chen Y, Trevi帽o LR, Sarabia SF, Hampton OA, Patel K, Mistretta TA, Zorman B, Thompson P, Heczey A, Comerford S, Wheeler DA, Chintagumpala M, Meyers R, Rakheja D, Finegold MJ, Tomlinson G, Parsons DW, L贸pez-Terrada D "." Hepatology. 2017 Jan; Pubmed PMID:
Memberships
- American Society of Clinical Oncology
- Children's Oncology Group
- American Society of Cell and Gene Therapy
Funding
- Sponsored Industrial Research Agreement (07/01/2021 - 06/30/2022) Grant funding from KUUR / Athenix
- Interleukin-15 and -21 armored Glypican-3-specific CAR T cells for patients with hepatocellular carcinoma (04/01/2019 - 03/31/2023) Grant funding from Cancer Prevention and Research Institute of Texas
- Genomic and functional characterization of CAR T cells in children with liver cancer (11/01/2018 - 10/31/2021) Grant funding from V Foundation
- T cells expressing an optimized Glypican-3-specific CAR for the immunotherapy of high-risk pediatric liver cancer (08/31/2018 - 08/30/2022) Grant funding from Cancer Prevention and Research Institute of Texas
- Natural Killer T cells with an IL-15-armored GD2-specific CAR for children with neuroblastoma (03/01/2018 - 02/28/2021) Grant funding from ALSF Biotherapeutics Award
- Therapeutic Activity of CAR-NKT cells in Children with neuroblastoma (03/01/2021 - 02/28/2023) Grant funding from American Cancer Society - St. Baldrick's Foundation
- IL15 and IL21 armored GPC3-CAR T cells for children with solid tumors - #R01CA258866 (01/01/2022 - 12/31/2026) Grant funding from National Institute of Health
Intellectual Property
- Design Patent #WO2016049459A1 (Pending)
- Design Patent #US20140255363A1 (Pending)
- Design Patent (Pending)
Languages
Hungarian
to edit your profile